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Purpose: The lung is the second most common site of metastasis from colorectal cancer. Of all patients who undergo a cu-
rative resection for colorectal cancer, 10% to 15% will develop lung metastasis. As a hepatic resection of colorectal liver me-
tastases results in improved survival, many reports have suggested that a pulmonary resection of a colorectal lung metas-
tasis would also improve survival. The aim of this study was to analyze the postoperative outcomes of and the prognostic 
factors for a surgical resection of a lung metastasis. 
Methods: Between August 1997 and March 2006, 27 patients underwent surgical resections for colorectal lung metastases 
at Seoul St. Mary’s hospital. A retrospective review of patients’ characteristics and various tumor factors was performed. 
Results: The mean interval between colorectal resection and lung metastasis was 24.0 ± 15.1 months. The overall 3- and 5- 
year survival rates were 76.5% and 22.2%, respectively. The mean follow-up after pulmonary resection was 39.5 ± 21.6 months 
(range, 3.3 to 115 months). Except for the existence of hilar-lymph-node metastasis (P < 0.001), no risk factors that we stud-
ied were statistically significant. Two patients had hilar-lymph-node metastasis. They survived for only for 3.3- and 11.6- 
months, respectively. 
Conclusion: In our study, we found that a pulmonary resection for metastases from colorectal cancer may improve sur-
vival in selected patients.
Keywords: Colorectal neoplasms; Neoplasm metastasis; Lung 
section contributes to improving the survival rate of the pa-
tients [2, 3]. The lung is the most frequent extraperitoneal met-
astatic site, and lung metastasis has been shown to develop in 
approximately 10% of the patients who undergo a curative re-
section for colorectal cancer [4]. Since most lung metastases 
are in a disseminated state at the time of diagnosis, cases for 
which a curative resection is indicated are rare, so most cases 
are treated by using conservative treatment or chemotherapy, 
which have been shown to be only limited help to patients [1]. 
Nevertheless, since Blalock reported a surgical resection for 
lung metastasis from colorectal cancer for the first time in 1944, 
surgical resection of lung metastasis has been performed for 
selected cases, and the 5-year survival rate after surgical re-
section of lung metastasis has been reported to range from 9% 
to 60%, depending on the investigator [1-6]. Therefore, in our 
study, among patients who underwent a curative resection for 
colorectal cancer, the outcomes of the surgical resection of 
lung metastasis and the prognostic factors affecting the sur-
vival rate were examined.
INTRODUCTION
Colorectal cancer is one of cancers whose incidence is most 
rapidly increasing in Korea. With the increasing incidence of 
colorectal cancer, the number of patients with distant metas-
tasis is also increasing, and for this, various treatment meth-
ods have been introduced, and treatment protocols have been 
changed [1]. Among the distant metastases, hepatic metastasis 
is presently the representative distant metastasis of colorectal 
cancer, and numerous studies have reported that surgical re-
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METHODS
One thousand two-hundred sixty-nine patients underwent 
surgery for colorectal cancer from August 1997 to March 2006 
at Seoul  St. Mary’s Hospital, The Catholic University of Korea, 
and lung metastasis was diagnosed in 259 cases. Surgical re-
section for lung metastasis was performed on 29 patients. Ex-
cluding 2 patients without sufficient data, the medical records 
of the remaining 27 patients (10.4%) were examined retrospec-
tively. Studies were conducted only on patients without other 
distant metastases and with metastases limited to the lung at 
the time of the detection of the lung metastasis, as confirmed 
by comprehensive preoperative evaluations. Factors affecting 
the survival rate were analyzed by examining age, gender, the 
site of the primary tumor, the disease stage, the interval from 
radical resection for colorectal cancer to the detection of lung 
metastasis, the carcinoembryonic antigen (CEA) value at the 
time of the detection of lung metastasis, the number of lung 
metastasis lesions, the size of the largest lesion, the surgical 
method for removing the lung metastasis, and the presence or 
absence of hilar-lymph-node metastasis. Based on the time of 
the detection of lung metastasis, we performed a Kaplan-Meier 
survival analysis, and the survival rates were compared by us-
ing the log-rank test; P-values less than 0.05 were considered 
to be significant.
RESULTS
A comparative analysis of the clinical features and the prog-
nostic factors for the 27 patients who underwent a surgical 
resection for lung metastasis is shown in Table 1. The mean 
age at the time of the detection of lung metastasis was 61.0 
years (range, 42 to 81 years), and regarding gender, 15 patients 
were males and 12 patients were females. Concerning primary 
cancer, tumour node metastasis (TNM) stage II was observed 
in 12 cases, stage III in 9 cases, and stage IV in 3 cases; the three 
patients with stage IV cancer had simultaneous lung metasta-
sis. As the site of colorectal cancer, rectal cancer was observed 
in 19 cases and colon cancer in 8 cases. Concerning surgery 
for colorectal cancer, a low anterior resection was performed 
in 13 cases, an abdominoperineal resection in 5 cases, an an-
terior resection in 3 cases, a right colectomy in 3 cases, and a 
Hartmann’s procedure in 2 cases. The mean interval from sur-
gery for colorectal cancer to the detection of lung metastasis 
was 24.0 ± 15.1 months. The mean follow-up period was 39.5 
± 21.6 months (range, 3.3 to 115 months). The 3-year survival 
rate and the 5-year survival rate for all entire patients were 
76.5% and 22.2%, respectively, and the mean survival period 
was 55.7 ± 8.1 months (Fig. 1). The average size of the lung 
metastasis lesions was 2.3 ± 1.6 cm. In regard to their numbers, 
a single metastasis was noted in 12 cases and multiple metas-
tases were noted in 15 cases, 7 of those being bilateral. In re-
gard to surgery, a wedge resection was performed in 21 cases, 
and a segmentectomy or a lobectomy was performed in 6 cases. 
No deaths related to lung resection were noted, and all patients 
Table 1. Characteristics of the primary cancer and pulmonary me-
tastasis 
Variables No. (%)
Mean  
survival (mo)
P- 
value
Sex
   Male
   Female
15 (56)
12 (44)
45.5 ± 3.3
  55.2 ± 12.9
0.811
Tumor location
   Colon
   Rectum
  8 (30)
19 (70)
40.2 ± 7.9
60.1 ± 9.9
0.597
Initial stage
   II
   III
   IV
12 (44)
  8 (30)
  3 (11)
50.8 ± 2.9
  55.4 ± 15.0
33.2 ± 8.8
0.524
Adjuvant chemotherapy
  No
  Yes
   1 (3.7)
   21 (77.7)
59.3
59.3 ± 9.7
0.791
Disease free interval
a
   Synchronous
   Within 24 mo
   After 24 mo
  3 (11)
10 (37)
14 (52)
33.2 ± 8.8
  56.0 ± 10.8
40.5 ± 4.1
0.735
Carcinoembryonic antigen   
  (preop.)
   < 5
   > 5
19 (70)
  7 (26)
 56.2± 8.9
37.1 ± 8.0
0.624
Number of metastases
   Solitary
   Multiple
12 (44)
15 (56)
  57.2 ± 12.6
44.0 ± 3.5
0.876
Unilateral vs. Bilateral
   Unilateral
   Biltearal
20 (74)
  7 (26)
54.3 ± 9.4
45.7 ± 4.5
0.993
Largest diameter of metastases
   Less than 2 cm
   Larger than 2 cm
17 (63)
10 (37)
40.9 ± 4.4
  69.2 ± 14.7
0.261
Type of surgery
   Wedge resection
   Segmentectomy or lobectomy 
21 (78)
  6 (22)
54.1 ± 8.3
40.2 ± 3.5
0.514
Hilar-lymph-node
   Positive
   Negative
2 (7)
25 (93)
  7.5 ± 4.2
59.5 ± 8.3
<0.001
Resection margin
   Positive
   Negative
  3 (11)
24 (89)
43.5 ± 2.5
55.2 ± 8.4
0.804
Chemotherapy
b
   No
   Yes
     2 (11.1)
   23 (85.2)
49.7 ± 9.7
  60.1 ± 10.5
0.836
aFrom colorectal cancer surgery to lung metastasis; 
bChemotherapy 
after lung resection.Journal of The Korean Society of
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recovered without special complications. Hilar-lymph-node 
metastasis was diagnosed in 2 cases, and the patients died after 
3.3 months and 11.6 months, respectively. As chemotherapy 
after pulmonary resections, the FOLFOX regimen was admin-
istered in 13 cases, the FOLFIRI regimen was administered in 
3 cases, 5-FU/leucovorin was administered in 4 cases, capeci-
tabine was administered in 3 cases, and no chemotherapy was 
administered in 2 cases. Recurrence was noted in 14 cases dur-
ing the follow-up observation period, and recurrence in the 
lung, 8 cases, was most prevalent. Among those 8, a re-resec-
tion was performed in 6 cases, and the remaining 2 patients 
were treated with chemotherapy. Other distant metastases were 
brain metastasis, bone metastasis, etc. (Table 2). 
In our study, when a surgical resection was performed for 
lung metastasis, depending on the presence or absence of hilar-
lymph-node metastasis, a significant difference in survival was 
shown (P < 0.001) (Fig. 2). No differences in survival due to 
other factors such as age, gender, the location of the primary 
tumor, the disease stage, the interval from resection of colorec-
tal cancer to the detection of lung metastasis, the CEA value 
at the time of the detection of lung metastasis, the number of 
metastasis lesions, the size of the largest metastasis lesion, the 
surgical method used to treat the lung metastasis, and the pres-
ence or absence of residual cancer on the lung resection sur-
face were observed (Table 1). In the multivariate analysis, the 
presence or absence of hilar-lymph-node metastasis was the 
only significant prognostic factor (P = 0.007).
DISCUSSION
In the past, lung metastasis of colorectal cancer was considered 
to be a disseminated disease and thus incurable, and chemo-
therapy and conservative treatments were considered to be 
major treatment options [1]. Nevertheless, recently, surgical 
resection for metastatic lesions has been reported to prolong 
survival; thus, surgical treatment for lung metastasis that de-
veloped after a curative resection of colorectal cancer has been 
used widely, and numerous studies on treatment methods after 
metastasis and on prognostic factors have been conducted [1, 
2, 4-6]. In studies reported recently, the 5-year survival rate 
after a pulmonary resection varies from 9 to 60%, but this is 
noticeably better than the approximately 5% survival rate in 
patients without treatment after lung metastasis, and in most 
studies, postsurgical complications or death was infrequent. 
Thus, a pulmonary resection is accepted as a safe and effective 
treatment method [5]. 
Generally accepted indications of surgery for metastatic lung 
lesions is 1) a complete resection of primary cancer can be per-
formed, 2) distant metastases other than lung metastasis are 
absent, 3) metastatic lung lesions can be completely resected, 
and 4) the patient should be able to withstand surgery [7]. Nev-
ertheless, recently, with efforts to improve pulmonary resec-
Table 2. Recurrence after a metastasectomy for colorectal lung me-
tastases
Recurrence site No. (%)
Lung   8 (57)
Bone   2 (14)
Brain 1 (7)
Chest wall   2 (14)
Cervical lymph nodes 1 (7)
Intraabdominal lymph nodes   2 (14)
Fig. 1. Overall survival of patients who underwent a pulmonary re-
section for colorectal lung metastasis. 
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Fig. 2. Cumulative survivals for positive and negative hilar-lymph-
node (LN) metastases. 
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tion techniques and to perform more aggressive treatments, 
the indications of pulmonary resection have been expanded 
in some cases. Indeed, in some cases, at the time of the detec-
tion of lung metastasis of colorectal cancer, metastases to other 
organs such as the liver have been present. MacAfee et al. [8] 
reported that a liver metastasis detected prior to surgery for 
lung metastasis was not a contraindication provided a curative 
liver resection was performed. In addition, pulmonary resec-
tions, which were applied to solitary lesions during the early 
period of performing pulmonary resections, have recently been 
applied to cases with bilateral lung metastasis provided a com-
plete resection was possible, and good results were obtained 
[9-11]. In our study, a pulmonary resection was performed in 
15 cases involving multiple metastatic lesions of which 7 in-
volved bilateral metastasis. For cases with multiple lesions, as 
well as cases with bilateral metastasis, surgical resections of all 
lesions were performed, and the patients recovered without 
special complications. In the statistical analysis, the survival 
rates were not significantly different when surgical resection 
for solitary lesions and surgical resection for lesions restricted 
to one side were compared.
Several studies analyzed prognostic factors affecting survival 
after a pulmonary resection. They reported serum CEA levels 
immediately prior to surgical treatment for lung metastasis 
lesions, the interval from radical resection for colorectal can-
cer to the diagnosis of lung metastasis lesions, and the pres-
ence or absence of previously-mentioned multiple lung lesions 
as prognostic factors [1, 7, 9, 11-13]. The serum CEA level is 
an index showing the size of the entire tumor, and it has been 
considered to be an index representing the ability of tumor 
cells to express serum CEA [14]. In addition, CEA itself has 
been shown to attach to cells and, thus, to be involved in the 
adhesion of tumor cells to host cells [15]. Hence, in patients 
whose serum CEA value is elevated higher than normal, the 
survival rate after surgical resection for metastatic lung lesions 
has been predicted to be poor. Nevertheless, even if the serum 
CEA value is elevated, the survival after surgical resection of 
metastatic lesions is better than it is in the untreated group; 
thus, an elevated serum CEA level should not be a contraindi-
cation of surgical treatment [8, 10]. Particularly, in cases with 
multiple metastases or bilateral metastases, if the serum CEA 
value is elevated during tests on patients on whom a pulmo-
nary resection is to be performed, special attentions should be 
paid and a comprehensive examinations of organs other than 
the lung and of the surgical area for colorectal cancer should 
be performed. In our study, when cases with elevated preop-
erative serum CEA were compared with normal cases, survival 
rates were not significantly different. In addition, in cases with 
multiple metastases, the serum CEA value was shown to be 
significantly elevated (P = 0.03); nonetheless, that did not af-
fect the survival rates, which is thought to be related to the 
fact that our study was conducted on a limited number of pa-
tients, so studies conducted on more patients are required.
Concerning whether the interval from curative treatment for 
primary cancer to the development of lung metastasis could 
be a prognostic factor, it varied with the report. A multicenter 
study on pulmonary resection for metastatic lung cancer in 
5,206 patients reported that the time to the development of 
lung metastasis might be a factor, together with whether the 
metastatic lesions had been completely resected or not and the 
number of metastatic lesions, that could be used to determine 
a prognosis for patients [11]. In the study reported by Rena et 
al. [9], the disease-free period was divided into three periods, 
0-11 months, 12-35 months, and longer than 36 months, and 
the survival rates after a pulmonary resection were compared. 
They reported that as the disease-free period became shorter, 
a worse prognosis was shown. However, other studies reported 
that the disease-free period did not have a significant effect 
on survival. Thus, this issue is still unresolved. In our study, 
similarly, the time to develop lung metastasis was shown not 
affect the survival rate of patients after a pulmonary resection. 
This variation of the disease-free period from one study to an-
other is thought to be due to the differences in the detection 
times of lung metastasis for various follow-up schedules and 
methods [16]. If such differences are to be reduced, multicenter 
studies according to standard treatment guidelines are required. 
At our hospital, for the detection of lung metastasis after sur-
gery for colorectal cancer, chest X-rays and serum CEA tests 
are performed every three months for the first 2 years after 
surgery, then at 6-months intervals for the next three years, 
and then annually after 5 years. If abnormal findings are de-
tected, additional comprehensive tests, such as CT and PET-
CT, were performed. Although some studies have reported that, 
together with the above prognostic factors, disease stage, the 
location of primary cancer, and the size of metastatic lesions 
are valuable as factors that can be used to provide prognosis 
after a pulmonary resection, in our study, theirs other factors 
had no statistical significance.
In our study, two patients had hilar-lymph-node metastasis, 
and the patients died 3.3 months and 11.3 months, respec-
tively, after the pulmonary resection. Since the number of pa-
tients was small, it is difficult to consider this result to be sta-
tistically significant; nonetheless, hilar-lymph-node metastasis 
may imply a disease with advanced state and should be consid-
ered as a poor prognostic factor. Okumura et al. [17] reported 
that in 100 patients with lung metastasis of colorectal cancer, 
hilar-lymph-node metastasis was detected in 15 patients, their 
5-year survival rate being 6.7%; a hilar lymphadenectomy did 
not improve the prognosis. Inoue et al. [18] reported, in a study 
conducted on 25 patients with lung metastasis, that the 5-year 
survival rate of patients with hilar-lymph-node metastasis was 
14.3%, which was significantly lower than the 49.5% 5-year 
survival rate of patients without hilar-lymph-node metastasis. 
Nonetheless, Goya et al. [19] reported, in a study conducted Journal of The Korean Society of
Coloproctology
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on 62 patients that the 5-year survival rate of all patients was 
42%, and the presence or absence of hilar-lymph-node metas-
tasis did not significantly affect the survival rate of patients af-
ter a pulmonary resection for metastatic lung lesions. In cases 
with metastatic tumors smaller than 3 cm, lymph node me-
tastasis was reported to have been detected only in 8% of the 
cases whereas in cases with metastatic tumors larger than 3.1 
cm, lymph node metastasis was detected in approximately 50% 
of the patients [1]. Thus one can conclude that as the size of 
the tumor becomes larger, the possibility of hilar-lymph-node 
metastasis becomes higher, and the possibility of complete re-
section is lower.  Hence, a large mestastatic tumor may indi-
cate poor survival. In fact, hilar-lymph-node metastasis is con-
sidered to be a series of processes through which metastatic 
lung cancer becomes systemic cancer [6]. In such a manner, 
hilar-lymph-node metastasis may imply disseminated metas-
tasis; thus, attention should be paid to the selection of surgical 
treatment. In addition, when surgery is selected as the method 
of treatment, whether or not a broad lymphadenectomy should 
be performed must be addressed. Based on such results, when 
a surgical resection for lung metastasis of colorectal cancer is 
performed, if hilar-lymph-node metastasis is suspected based 
on preoperative evaluations, comprehensive tests assessing the 
presence of metastasis in other organs are thought to be re-
quired. If surgery is performed, studies on the variation in the 
outcomes according to the surgical method used for treatment 
should be conducted, and studies on the necessity of additional 
treatments, such as postoperative chemotherapy or radiation 
therapy, should be conducted in parallel.
If a pulmonary resection is selectively performed on patients 
with lung metastasis after a curative resection of colorectal 
cancer, the survival rate may be improved. Nonetheless, a pul-
monary resection probably will not improve the survival rate 
of patients with hilar-lymph-node metastasis identified by tests 
performed prior to the pulmonary resection. In addition, anal-
yses of the effects of pulmonary resection on and of the prog-
nostic factors for lung metastasis patients are thought to be 
required.
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